Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
Agreed. Although this is a cool idea and will benefit some patients, this is a niche market. When I look at small caps like this, I would like to foresee several multiple of return over the long haul. I am biased against this one. Multiple devices targeting these difficult to treat lesions have come and gone, but none have ever been miraculous. Severe calcific atherosclerosis is the end stage of this horrible disease, and treating a subset of these patients is important; so, kudos to this company. However, I don't see this company as a game changer like robotic surgery or endovascular aneurysm repair.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.